Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies
Дата публикации: 12-08-2026 07:08:00

Evidence for efficacy is based on the results from the Precision-T study

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC013.1329-07-2026
2FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC5724-06-2026
3FDA одобрило терапию Orca Bio для лечения лейкоза5702-07-2026
4FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab for First-Line Treatment of TNBC013.9905-08-2026
5STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class04.2314-08-2026
6FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma09.1822-07-2026
7EMA Recommends Extension of Therapeutic Indications for Epcoritamab08.0424-07-2026
8FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer5508-07-2026
9FDA approves gene therapy for children with sickle cell disease ages 2+5709-07-2026
10New PILL for psoriasis approved... giving hope to millions suffering from debilitating skin condition05.2618-03-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 14.59. Источник: www.esmo.org.